Status:
TERMINATED
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Participants
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy ...
Eligibility Criteria
Inclusion
- Healthy male and female (i e, women not of childbearing potential) participants
- Body Mass Index (BMI) of 18 to 32 kg\^m2 and total body weight ≥ 50 kg
- Parts A, B, and D: Participants without restriction on ethnicity
- Part C: Participants of Japanese ethnicity (both biological parents are ethnically Japanese)
Exclusion
- Clinically significant medical, psychiatric and/or sound social reason, as determined by the investigator
- Any major surgery within 3 months of study intervention administration
- Participation in another clinical trial concurrent with this study
- Note: Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
January 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 16 2024
Estimated Enrollment :
267 Patients enrolled
Trial Details
Trial ID
NCT06144697
Start Date
January 29 2024
End Date
October 16 2024
Last Update
February 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Anaheim, California, United States, 92801
2
Local Institution - 0003
Austin, Texas, United States, 78744